New Qld lab to produce personalised cancer vaccines

A new facility at The University of Queensland is set to produce cancer vaccines tailored to individual patients.

The lab at UQ’s Australian Institute for Bioengineering and Nanotechnology (AIBN) will bring together the equipment and expertise to enable the design, manufacture and delivery of new mRNA cancer vaccines.

Supported by $3.3 million funding from the Medical Research Future Fund’s (MRFF) National Critical Research Infrastructure program, the facility will provide the local research community with vaccines that match the specific treatment needs of each patient.

Dr Seth Cheetham, Deputy Director of AIBN’s BASE facility, said, “Personalised mRNA cancer vaccines are now being used to train the body’s immune system to recognise and eradicate cancer cells.

“Despite the huge potential, Australian researchers haven’t had the necessary infrastructure to build these vaccines, leading to a critical gap in the local drug development pipeline.

“This lab changes that, with a leading team of investigators in a purpose-built space, working with local industry and academics to progress a range of high-quality mRNA cancer vaccine candidates from design through to preclinical evaluation, with the aim of enabling future clinical trials.”

The mRNA cancer vaccine hub is expected to be operating in BASE by late 2024. The facility already provides mRNA for research and pilot studies, and since its launch in 2021 has provided academic and industry partners with more than 300 experimental-grade vaccines.

The new lab was one of four UQ projects funded in the latest MRFF grant round, adding to the $6.6 million funding awarded to BASE in 2023 to boost clinical mRNA production capabilities.

AIBN Director Professor Alan Rowan said the hub would complement Australia’s existing research strengths in oncology and affirm AIBN as a therapeutics and personalised medicine pipeline.

“Governments and society want sustainable innovation that enables high-quality research and delivers translatable outcomes,” Rowan said.

“The mRNA cancer vaccine hub is the latest example of how AIBN combines world-class infrastructure and technical expertise to bridge the gap between research and clinical development.”

The five-year program will also bring together partner investigators from UQ, QIMR-Berghofer, Mater Research, Garvan Institute of Medical Research and the Queensland Children’s Hospital.

Image caption: Dr Seth Cheetham, Deputy Director of AIBN’s BASE facility. Image: Supplied.